Ahmed Hasan Althobaiti

Dr. Ahmed Hasan Althobaiti

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2025 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
SASalman Aljarallah
Salman Aljarallah
AAAhmed Hasan Althobaiti
Ahmed Hasan Althobaiti
AAAhmad Abdulaziz Abulaban
Ahmad Abdulaziz Abulaban
FAFahad AlDosari
Fahad AlDosari
SASaleh Alhasan
Saleh Alhasan
MJMohammed Al Jumah
Mohammed Al Jumah
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune demyelinating disorder of the central nervous system (CNS) that predominantly affects the optic nerve and spinal cord. Despite advancements in understanding NMOSD, challenges in management remain. Recommendations by Saudi experts on the management of NMOSD were published in 2022. However, regulatory approval of new treatments and recent developments in the understanding of MOGAD necessitated an update to the recommendations. This study aimed to develop expert-driven, evidence-based, up-to-date consensus recommendations for the management of NMOSD in Saudi Arabia. A multidisciplinary panel of neurologists, neuroimmunologists, epidemiologists, and pharmacists was convened under the Saudi Neurology Society - Multiple Sclerosis Chapter. The process included a systematic literature review and a GRADE assessment of 56 studies. Recommendations were drafted and refined by two independent reviewers before being subjected to a two-round Delphi survey where experts voted on the statements. The consensus was reached through iterative voting, feedback, and refinement rounds to ensure clarity and alignment with clinical practice needs. The finalised recommendations addressed key areas, including diagnostic strategies, diagnostic criteria, and acute and chronic treatments in NMOSD, as well as recommendations regarding the diagnosis and treatment of MOGAD. Treatment recommendations covered acute attack management, initial immunosuppressive therapies, treatment duration, and prognostic factors at diagnosis for failure of first-line treatments. The use of Rituximab, azathioprine (Imuran), mycophenolate mofetil (CellCept), and newer therapies such as ravulizumab, tocilizumab, inebilizumab, satralizumab, and eculizumab is also discussed with the newer therapies offering potential advantages in specific patient populations. While newer therapies show promising efficacy, variations in safety, accessibility, and patient response highlight the need for further evaluation to determine their optimal role in treatment regimens. GRADE assessments indicated moderate to high certainty for most statements based on study design, sample size, and consistency of evidence. This expert consensus provides evidence-based guidance for the diagnosis and management of NMOSD in Saudi Arabia, striking a balance between clinical evidence and expert opinion where data gaps exist. It emphasises individualised care, antibody testing, and long-term immunosuppressive strategies while highlighting the need for further research on treatment duration and failure criteria.

16 April 2025 in BMC Neurology
Verified
Journal Article
Open access
PDF file
SKSalahuddin Khan
Salahuddin Khan
MAMeshal Alzakari
Meshal Alzakari
FAFaisal Alzkari
Faisal Alzkari
RARenad Alsuhaibani
Renad Alsuhaibani
AAAlanoud Alabdulkarim
Alanoud Alabdulkarim
AAAhmed Hasan Althobaiti
Ahmed Hasan Althobaiti
Parkinson’s disease is a progressive disease that causes damage to parts of the brain, especially the substantia nigra. It is the most common motor brain condition. To investigate the knowledge, awareness, attitudes, and practices toward Parkinson’s disease among the general population in Saudi Arabia. This cross-sectional study was conducted in Saudi Arabia from July 20 to November 20, 2024, targeting adults aged 18 years and older. Participants (n = 385) were randomly selected via social media platforms, using a bilingual (Arabic and English) online questionnaire. The survey included demographics, knowledge, awareness, attitudes, and practices. Data was analyzed using SPSS (version 28), with ethical approval obtained. A total of 330 participants were surveyed, mostly young (292, 88.5% aged 18–24), female (269, 81.5%), and students (281, 85.2%). Nearly half (162, 49.1%) had heard of PD, but only 81 (24.5%) showed good knowledge, with misconceptions about causes and treatment. Commonly recognized symptoms included hand tremors (292, 88.5%) and poor balance (210, 63.6%), while awareness of non-motor symptoms was low. Most participants (319, 96.7%) supported public education, and 310 (93.9%) recommended social support for PD patients. This study emphasizes the lack of public knowledge and awareness regarding Parkinson’s disease, its symptoms, and its causes in Saudi Arabia. The results highlight the need for educational efforts to improve understanding and address misconceptions. Neuroscience.


3 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AAAhmed Hasan Althobaiti
Ahmed Hasan Althobaiti
AAAfnan A. Alnughaimish
Afnan A. Alnughaimish
SASaif S. Alqahtani
Saif S. Alqahtani
FAFahad Aldosari
Fahad Aldosari
Background: Rituximab is used off-label for multiple sclerosis (MS), and biosimilar substitution raises a distinct extrapolation challenge, as MS is not an approved indication for the reference product. Real-world nonmedical-switching data inform biosimilar appropriateness decisions by clinicians, societies, and payers. Objective: To report the effectiveness and tolerability of nonmedical switching from originator (MabThera®) to biosimilar rituximab (Truxima®) in people with MS (pwMS). Methods: A retrospective, single-center observational cohort study of 50 pwMS switched after at least two originator infusions, followed for two years. Results: Annualized relapse rate declined from 0.45 (95% CI 0.28–0.68) pre-rituximab to 0.02 (95% CI 0.00–0.13) on originator and 0.00 (95% CI 0.00–0.05) on biosimilar (p = 0.367 between products). In paired imaging analysis (n = 29), the proportion with active scans declined progressively (50.0%, 34.5%, 17.2%; Cochran’s Q, p = 0.040), with no difference between the originator and biosimilar periods (McNemar, p = 0.227). B-cell depletion deepened progressively. All patients remained on biosimilar through the end of follow-up. Conclusion: Nonmedical switching from originator to biosimilar rituximab was associated with comparable clinical and radiological outcomes, supporting its use in pwMS without concern for inferior efficacy or diminished tolerability.

17 August 2026 in medRxiv
Verified
Preprint
Open access
AAAhmed Hasan Althobaiti
Ahmed Hasan Althobaiti
NANora Abanmi
Nora Abanmi
Background: Late-onset neutropenia (LON) is an infrequently reported, unpredictable side effect of anti-CD20 therapy, with incidence varying by agent, diagnosis, and screening protocol. Objective: The primary objective of this cross-sectional, retrospective study was to estimate the proportion of patients who developed LON over 13 months (April 2023-April 2024). Methods: Consecutive adult patients diagnosed with central nervous system (CNS) autoimmunity who received at least one rituximab(RTX) or ocrelizumab(OCR) infusion between January 2016 and March 2024 were included; patients who switched to another immunotherapy, had no post-treatment blood draw, or had unverifiable infusion records were excluded. LON events were assessed using all post-treatment CBCD blood draws during this period. Results: A total of 171 patients were enrolled: 141 received rituximab and 30 received ocrelizumab. A total of 319 post-treatment blood tests were performed. Sixteen patients (16/171) had neutropenia (9.4%, 95% CI 5.8-14.7): 12 on rituximab (8.5%) and 4 on ocrelizumab (13.3%; p=0.487). LON occurred at a median of 158 days (130-188) since the last infusion. All patients were asymptomatic, mostly had Grade 1 neutropenia (15/16, 93.8%). BMI (22.2 vs. 27.5 kg/m2, p=0.001) and prior natalizumab exposure (37.5% vs. 14.2%, p=0.023) were significantly different between neutropenic and non-neutropenic patients. Conclusion: The proportion of patients with LON in this cohort was higher than most previously reported, with all cases asymptomatic. Lower BMI and prior natalizumab exposure emerged as potential risk factors warranting further investigation. Larger, prospective studies with standardized surveillance are needed to establish the true frequency and risk factors.